Recent Stories
Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: RobotsBlack October Wasn't an Attack Wave. It Was a Warning.Extreme Ownership Means Ultimate Achievement – NASA Culture Shift
← Back to the board
Money

HHS ASPR awarded Battelle Memorial Institute contract 75A50123F61002 to repurpose panhematin and disulfiram as potential medical countermeasures against knockdown agents.

Why it’s here: ASPR-funded medical countermeasure development against chemical knockdown agents falls under biosecurity and pandemic/CBRN preparedness (BARDA/ASPR), a biotechnology policy area in scope, though it is a drug repurposing contract rather than a novel-technology or policy-focused notice.

Trace across the board

Item

Connected

11 links

About

  • Department of Health and Human Services

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

HHS ASPR awarded Battelle Memorial Institute contract 75A50123F61002 to repurpose panhematin and disulfiram as potential medical countermeasures against knockdown agents. — The Wave